Novacyt: hit by news from UK
(CercleFinance.com) - Novacyt shares are down 3% after the latest news regarding the marketing of its Covid-19 tests in the UK following the implementation of the 2021 medical device regulations passed by the UK Health Security Agency (CTDA).
Since 1 November, the company has only been selling the PROmate COVID-19 test in the UK until the CTDA completes its review of the nine additional products submitted, which could only be sold until 31 October.
If no further products are added to the CTDA register, the impact on annual revenues for 2021 will be around 3 million pounds, the French clinical diagnostics specialist warned.
Copyright (c) 2021 CercleFinance.com. All rights reserved.